Human Pancreatic Secretory Trypsin Inhibitor
Author(s) -
Tania Marchbank,
Tom C. Freeman,
Raymond J. Playford
Publication year - 1998
Publication title -
digestion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.882
H-Index - 75
eISSN - 1421-9867
pISSN - 0012-2823
DOI - 10.1159/000007485
Subject(s) - proteases , psti , pancreas , mucus , biology , protease inhibitor (pharmacology) , pancreatic elastase , gastrointestinal tract , trypsin , trypsin inhibitor , endocrinology , medicine , elastase , biochemistry , enzyme , immunology , dna , ecology , restriction enzyme , human immunodeficiency virus (hiv) , antiretroviral therapy , viral load
Pancreatic secretory trypsin inhibitor is a potent protease inhibitor which was originally identified in the pancreas. It has subsequently been shown to be present in mucus-secreting cells throughout the gastrointestinal tract and also in the kidney, lung and breast. Its major roles are likely to be to prevent premature activation of pancreatic proteases and to decrease the rate of mucus digestion by luminal proteases within the stomach and colon. In addition, PSTI increases the proliferation of a variety of cell lines and stimulates cell migration, possibly acting via the EGF receptor. These findings suggest that PSTI may also be involved in both the early and late phases of the healing response following injury. Further studies including the production of transgenic overexpression and knockout models should help elucidate the physiological function of this peptide.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom